Popular Articles

Doctors Talk Frankly About What Encourages And Impedes Early Diagnosis Of Alzheimer's
A doctor"s positive attitude to Alzheimer"s diagnosis and their trusting, personal relationships with local dementia support service providers are powerful enablers for early diagnosis of Alzheimer"s, according to new research reported at the Alzheimer"s Association 2009 International Conference on Alzheimer"s Disease (ICAD 2009) in Vienna.
generic viagra online
Zysolin(TM) Pre-clinical Data Supports Once-a-day Dosing In Humans
AlphaRx (OTC BB:ALRX) is pleased to report a significant breakthrough in the development of Zysolin(TM), an inhaled Tobramycin nanoparticle formulation utilizing the company"s proprietary drug delivery platform, and intended for the adjunctive treatment of Pseudomonas Aeruginosa Pneumonia in intubated and mechanically-ventilated patients (VAP).
News of the day
BRIT1 Allows DNA Repair Teams Access To Damaged Sites
Like a mechanic popping the hood of a car to get at a faulty engine, a tumor-suppressing protein allows cellular repair mechanisms to pounce on damaged DNA by overcoming a barrier to DNA access.
Nutrition

Positive Long-Term Data For BENLYSTA (formerly LYMPHOSTAT-B(R)) In Patients With Active Lupus

Human Genome Sciences (HGS) has reported continuation data from a Phase II study of BENLYSTA™ (belimumab, formerly LymphoStat-B®) showing sustained improvement in patients with active systemic lupus after four years of treatment. The data was presented at the EULAR 2009 scientific meeting in Copenhagen, Denmark. Early results from a 52-week Phase III study of BENLYSTA™ are expected to be announced in July and results from a 76-week study are scheduled to be released in November. BENLYSTA™ is being co-developed and commercialized by HGS and GlaxoSmithKline (GSK). The HGS website has the full release about this additional Phase II data. Lupus Foundation of America


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):